Dr. Small is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1825 4th St
San Francisco, CA 94143Phone+1 415-476-4616Fax+1 415-353-7107- Is this information wrong?
Education & Training
- University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 1988 - 1989
- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1985 - 1988
- Case Western Reserve University School of MedicineClass of 1985
Certifications & Licensure
- CA State Medical License 1987 - 2024
- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2004-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Join now to see all
Clinical Trials
- Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors Start of enrollment: 1994 Sep 01
- SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer Start of enrollment: 1995 May 01
- Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer Start of enrollment: 1996 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance).Jai N Patel, Chen Jiang, Kouros Owzar, Daniel L Hertz, Janey Wang, Flora A Mulkey, William K Kelly, Susan Halabi, Yoichi Furukawa, Cameron Lassiter, Susan G Dorsey, Pa...> ;The Pharmacogenomics Journal. 2024 Mar 4
- Immune modulation with RANKL blockade through denosumab treatment in patients with cancer.Chang, H., Marquez Garcia, J., Chen, B., Kim, D., Cheng, M., Liu, E., Yang, H., Zhang, L., Sinha, M., Cheung, A., Kwek, S., Chow, E., Bridge, M., Aggarwal, R., Friedla...> ;Cancer Immunology Research. 2024 Jan 26
- Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced P...Chi, K., Chowdhury, S., Bevans, K., Bhaumik, A., Saad, F., Chung, B., Oudard, S., De Porre, P., Brookman-May, S., McCarthy, S., Mundle, S., Uemura, H., Small, E., Kars...> ;European Urology Oncology. 2023 Dec 9
- Join now to see all
Journal Articles
- First-in-Human Phase I Study of CTT1057, a Novel 18F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate CancerSpencer C Behr, Hao G Nguyen, Thomas A Hope, Kirsten L Greene, Matthew R Cooperberg, Robert R Flavell, Eric J Small, Peter R Carroll, Journal of Nuclear Medicine
- Corrigendum to ‘Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised ...Toni K Choueiri, Olwen Hahn, Thomas Olencki, Eric J Small, Shaker Dakhil, Darren R Feldman, European Journal of Cancer
- Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall SurvivalEric J Small, David I Quinn, Clinical Cancer Research
Authored Content
- Corrigendum to ‘Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-Free Survival by Independent Review and Overall Survival Update’ [Eur J Cancer 94 (May 2018) 115–125]September 2018
- Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-Free Survival by Independent Review and Overall Survival UpdateApril 2018
Press Mentions
- NEUVOGEN Appoints Dr. Mark W. Frohlich, a World-Renowned Immunotherapy Expert to Its Board of Directors and Scientific Advisory BoardAugust 23rd, 2021
- Trial Update for Apalutamide in Nonmetastatic Castration-Resistant Prostate CancerFebruary 14th, 2019
- UCSF and MGH: Apalutamide Delays Progression of Nonmetastatic, Castration-Resistant Prostate CancerFebruary 8th, 2018
- Join now to see all
Grant Support
- Prostate Cancer ProgramNational Cancer Institute2007–2011
- 04557: A Phase I/II Study Of Docetaxel/Prednisone And PTK 787/Zk 222584 In PRNational Center For Research Resources2005
- Effects Of Bicalutamide Monotherapy On Bone Density In Prostate CancerNational Center For Research Resources2004–2005
- Evaluation Of Continuous Infusion Gallium Nitrate For Advanced Bladder CarcinomaNational Center For Research Resources1997
- Study Of Pyrazoloacridine For Treatment Of Hormone Refractory Prostate CancerNational Center For Research Resources1996–1997
- Evaluation Of Continuous Infusion Gallium Nitrate For Advanced Bladder CancerNational Center For Research Resources1996
Hospital Affiliations
- UCSF Medical CenterSan Francisco, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: